Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.
Launched by HÔPITAL NOVO · Dec 5, 2017
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
A total of forty participants were included in this case-control study over a fifteen months period. The participants were divided in two equal groups. The case group (TXA group) was treated with a daily oral administration of two grams of tranexamic acid whereas the control group (noTXA group) was not treated. The data that has been recorded is the gender, the age, the implant volume (cc), the shape of the implant (round or anatomical), the type of surgical pocket (pre-muscular or retro-muscular), the texture of the implant (textured or smooth), the operating time (in minutes), the blood p...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Woman with Primary Breast Augmentation
- Exclusion Criteria:
- • Past History of Thromboembolism
- • Use of anticoagulant or platelet-inhibiting drugs
- • Severe Co-morbidity (ASA III)
- • Pre-pectoral Implant Pocket Location
- • Breast lipofecting
About Hôpital Novo
Hôpital Novo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a strong emphasis on collaboration and ethical practices, Hôpital Novo partners with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Their commitment to patient safety, data integrity, and regulatory compliance ensures that all research initiatives are conducted to the highest standards, ultimately contributing to the development of new treatments and therapies that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Thomas COLSON
Principal Investigator
Hôpital NOVO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials